Navigation Links
Amylin Comments on RiskMetrics Report
Date:5/15/2009

Urges Stockholders to Vote FOR Amylin Director Nominees on the Blue Proxy Card Today

RiskMetrics Splits Recommendation in Proxy Contest

SAN DIEGO, May 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today issued the following statement in response to a report issued by RiskMetrics Group (formerly Institutional Shareholder Services) regarding Amylin's Annual Meeting of Stockholders to be held on May 27, 2009:

It is important for shareholders to note that RiskMetrics split its recommendation, supporting only three out of five nominees proposed by Carl Icahn and Eastbourne Capital Management, L.L.C. We are confident that our slate of nominees is the right Board to lead Amylin. We are disappointed that RiskMetrics has recommended three dissident nominees to our annually-elected Board. The Company urges shareholders to vote FOR Amylin's highly-qualified Director nominees who have extensive experience in biopharmaceuticals and diabetes, as well as the valuable sales and marketing expertise necessary to most effectively guide Amylin. We believe that our nominees have better qualifications relevant to our business.

Importantly, Amylin's Board and management team have recognized and embraced the need for change, with two new independent Director nominees, Paul N. Clark, former Chairman, Chief Executive Officer and President of Icos Corporation, and Paulo F. Costa, former President and Chief Executive Officer of Novartis U.S. Corporation. Both bring additional commercial and operational expertise in the biopharmaceutical industry, which are key attributes requested by our shareholders.

Over the course of the past six months, Amylin has also taken the necessary steps to effect change in its business strategy and increase long-term shareholder value, including:
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
2. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
3. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
4. Amylin Issues Statement in Response to Carl Icahn
5. Icahn Asks Amylin to Allow Discussions With Eastbourne
6. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
7. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
8. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
9. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
10. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
11. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" ... a Canadian Patent for Inhibition or Reversal of ... claims using thymosin beta 4, various fragments and ... purposes.  The patent will expire in 2021. ... ) RegeneRx is focused on ...
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... September 30, 2014 OriginOil Inc. (OTC/QB: ... chemical-free process to clean up large quantities of water, ... Riggs Eckelberry reported on the launch of the company's ... site provided by partner STW Resources . , ... barrels per day (bpd) and achieved a 99.8% reduction ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... partnership focusing on commercializing market-relevant biohealth innovations and increasing ... , announced today that venture capitalist, Tania ... a strategic advisor. Dr. Fernandez will be a member ... Fund, which will provide up to $50 million in ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the ... 2009. All dollar amounts referenced herein are in Canadian dollars ... and cash equivalents totaled $7.3 million, compared with $8.6 million ... for the three months ended February 28, 2009 of $1.9 ...
... Wash., April 13 BioLife Solutions, Inc.,(OTC ... marketer of proprietary,cGMP hypothermic storage and cryopreservation ... announced that the Rutgers University ... university-based biologics repository,has adopted the Company,s CryoStor ...
... Cell Biosciences, Inc., a provider of nanoproteomic analysis systems ... a landmark study by a research team from ... Felsher, Associate Professor of Oncology, was senior author on ... serial analysis of oncoprotein activation in clinical samples", appeared ...
Cached Biology Technology:Vasogen Announces First Quarter 2009 Results 2Vasogen Announces First Quarter 2009 Results 3Vasogen Announces First Quarter 2009 Results 4Vasogen Announces First Quarter 2009 Results 5Vasogen Announces First Quarter 2009 Results 6Vasogen Announces First Quarter 2009 Results 7Vasogen Announces First Quarter 2009 Results 8Vasogen Announces First Quarter 2009 Results 9Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 2Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media 3Cell Biosciences Announces Publication in Nature Medicine 2
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... schemes that allow payments to landholders for planting trees, ... of carbon from the atmosphere. But they will have ... supply problems, if other benefits and disbenefits from revegetating ... land-use decisions, according to an article published in the ...
... Ky. - Does gum disease indicate future joint problems? ... association between two prevalent chronic inflammatory diseases - periodontal ... have remained unclear. In an article published today ... of Dentistry Oral Health and Systemic Diseases group researcher ...
... cancer drug, called Gamitrinib, for trial in humans, The Wistar ... Department of Defense,s Congressionally Directed Medical Research Program. ... the data necessary to allow the use of Gamitrinib in ... file an Investigational New Drug application with the US Food ...
Cached Biology News:Bacteria responsible for gum disease facilitates rheumatoid arthritis 2Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use 2Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use 3
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z36,327-8) or contact ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: